

November 29, 2022

The Manager, Listing Department
The National Stock Exchange of India Ltd.
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai - 400 051
NSE Symbol : PANACEABIO

BSE Limited
Corporate Relationship Department,
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai - 400 001
BSE Scrip Code: 531349

Sub: Disclosure of Related Party Transactions under Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,


Pursuant to Regulation 23(9) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular no. SEBI/HO/CFO/CMD1/CIR/P/2021/662 dated November 22, 2021, please find enclosed disclosure of related party transactions for half year ended September 30, 2022.

This is for your kind information and record please.

Thanking you,

Sincerely yours,
For **Panacea Biotec Ltd.**




Vinod Goel
Group CFO and Head Legal
& Company Secretary



Encls: As Above

B1 Extn. /G3, Mohan Co-op Indl. Estate,
Mathura Road, New Delhi -110044
Email: vinodgoel@panaceabiotec.com
Phone: D.I.D. +91-11-4167 9015
Fax: +91-11-4167 9070

Panacea Biotec Ltd.

CIN: L33117PB1984PLC022350

Registered Office: Ambala-Chandigarh Highway, Lalru - 140 501, Punjab, India. Ph.: +91-1762-505900, Fax: +91-1762-505906.
e-mail: corporate@panaceabiotec.com website: www.panaceabiotec.com


Related Party Transactions for half year ended September 30, 2022

(Rs. in million)


											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken								
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other Related Party Transaction	Value of the related party transaction as approved by the audit committee (Rs. in million)	Remarks on approval by audit committee	Value of transaction during the reporting period (Rs. in million)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments					Details of the loans, inter-corporate deposits, advances or investments	
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance (Rs. in million)	Closing balance (Rs. in million)	Nature of indebtedness (loan/ issuance of debt / any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan / advance / inter-corporate deposit / investment)	Interest Rate (%)	Tenure
1	Panacea Biotech Limited		Adveta Power Pvt Ltd.		Joint Venture	Any other transaction	Rental Income	As approved by Audit Committee and Board	0.01	0.32	0.34								
2	Panacea Biotech Limited		Adveta Power Pvt Ltd.		Joint Venture	Investments		As approved by Audit Committee and Board	-	0.90	0.90								
3	Panacea Biotech Limited		Dr. Rajesh Jain		Managing Director	Interest paid		As approved by Audit Committee and Board	7.57	181.76	153.16								
4	Panacea Biotech Limited		Dr. Rajesh Jain		Managing Director	Remuneration		As approved by Nomination and Remuneration Committee, Audit Committee and Board	3.88	-	-								
5	Panacea Biotech Pharma Ltd.		Manjula Upadhyay		Independent Director	Any other transaction	Sitting Fees	As approved by Board	0.15	-	-								
6	Panacea Biotech Limited		Meyten Realtech Pvt.Ltd		Subsidiary	Any other transaction	Rental Income	As approved by Audit Committee and Board	0.01	0.11	0.13								
7	Panacea Biotech Limited		Meyten Realtech Pvt.Ltd		Subsidiary	Interest received		As approved by Audit Committee and Board	0.07	0.09	0.16								
8	Panacea Biotech Limited		Meyten Realtech Pvt.Ltd		Subsidiary	Loan		As approved by Audit Committee and Board	1.50	0.80	2.30								
9	Panacea Biotech Limited		Meyten Realtech Pvt.Ltd		Subsidiary	Investments		As approved by Audit Committee and Board	-	0.10	0.10								
10	Panacea Biotech Limited		MR Lex Corp LLP		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Purchase of goods or services		As approved by Audit Committee and Board	0.41	0.51	0.57								
11	Panacea Biotech Limited		Mr. Ankesh Jain		Whole - time Director	Remuneration		As approved by Nomination and Remuneration Committee, Audit Committee and Board	1.39	-	-								



											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken								
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other Related Party Transaction	Value of the related party transaction as approved by the audit committee (Rs. in million)	Remarks on approval by audit committee	Value of transaction during the reporting period (Rs. in million)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments		
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance (Rs. in million)	Closing balance (Rs. in million)	Nature of indebtedness (loan/ issuance of debt / any other etc.)	Detail of other indebtedness	Cost	Tenure	Nature (loan / advance / inter-corporate deposit / investment)	Interest Rate (%)	Tenure
12	Panacea Biotech Limited		Mr. Ashwani Jain		Chief Operating Officer	Remuneration		As approved by Nomination and Remuneration Committee, Audit Committee and Board	1.48	-	-								
13	Panacea Biotech Limited		Mr. Bhupinder Singh		Independent Director	Any other transaction	Sitting Fees	As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.10	-	-								
14	Panacea Biotech Limited		Mr. Devender Gupta		CFO and Head IT	Remuneration		As approved by Nomination and Remuneration Committee, Audit Committee and Board	2.79	-	-								
15	Panacea Biotech Limited		Mr. Harshet Jain		Member of Promoter Group	Remuneration		As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.38	-	-								
16	Panacea Biotech Limited		Mr. K. M. Lal		Independent Director	Any other transaction	Sitting Fees	As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.15	-	-								
17	Panacea Biotech Limited		Mr. Mukul Gupta		Independent Director	Any other transaction	Sitting Fees	As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.10	-	-								
18	Panacea Biotech Limited		Mr. N. N. Khamitkar		Independent Director	Any other transaction	Sitting Fees	As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.13	-	-								
19	Panacea Biotech Limited		Mr. Narotam Kumar Juneja		Non-Executive Director	Any other transaction	Sitting Fees	As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.10	-	-								



										Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken									
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other Related Party Transaction	Value of the related party transaction as approved by the audit committee (Rs. in million)	Remarks on approval by audit committee	Value of transaction during the reporting period (Rs. in million)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments		
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance (Rs. in million)	Closing balance (Rs. in million)	Nature of indebtedness (loan/ issuance of debt / any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan / advance / intercorporate deposit / investment)	Interest Rate (%)	Tenure
20	Panacea Biotec Limited		Mr. R. L. Narasimhan		Independent Director	Any other transaction	Sitting Fees		As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.14	-	-							
21	Panacea Biotec Limited		Mr. Sandeep Jain		Joint Managing Director	Remuneration			As approved by Nomination and Remuneration Committee, Audit Committee and Board	3.60	-	-							
22	Panacea Biotec Limited		Mr. Soshil Kumar Jain		Chairman	Interest paid			As approved by Audit Committee and Board	6.79	159.65	152.72							
23	Panacea Biotec Limited		Mr. Soshil Kumar Jain		Chairman	Remuneration			As approved by Nomination and Remuneration Committee, Audit Committee and Board	5.74	-	-							
24	Panacea Biotec Limited		Mr. Tanish Jain		Relative of Promoter	Remuneration			As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.22	-	-							
25	Panacea Biotec Limited		Mr. Vinod Goel		Group CFO and Head Legal & CS	Remuneration			As approved by Nomination and Remuneration Committee, Audit Committee and Board	3.39	-	-							
26	Panacea Biotec Limited		Mrs. Manjula Upadhyay		Independent Director	Any other transaction	Sitting Fees		As approved by Nomination and Remuneration Committee, Audit Committee and Board	0.10	-	-							
27	Panacea Biotec Limited		Neophar Alipro Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Rental Income		As approved by Audit Committee and Board	0.09	-	-							



											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken									
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other Related Party Transaction	Value of the related party transaction as approved by the audit committee (Rs. in million)	Remarks on approval by audit committee	Value of transaction during the reporting period (Rs. in million)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance (Rs. in million)	Closing balance (Rs. in million)	Nature of indebtedness (loan/ issuance of debt / any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan / advance / intercorporate deposit / investment)	Interest Rate (%)	Tenure	Secured/ unsecured
28	Panacea Biotech Limited		Panacea Biotech (International) S.A.,		Subsidiary	Loan		As approved by Audit Committee and Board	-	96.79	96.79									
29	Panacea Biotech Limited		Panacea Biotech (International) S.A.,		Subsidiary	Any other transaction	Provision made on loan/advances	As approved by Audit Committee and Board	-	96.79	96.79									
30	Panacea Biotech Limited		Panacea Biotech (International) S.A.,		Subsidiary	Investments		As approved by Audit Committee and Board	-	34.36	34.36									
31	Panacea Biotech Limited		Panacea Biotech (International) S.A.,		Subsidiary	Any other transaction	Provision for impairment of Investment	As approved by Audit Committee and Board	-	34.36	34.36									
32	Panacea Biotech Limited		Panacea Biotech Germany		Indirectly wholly owned subsidiary	Interest received		As approved by Audit Committee and Board	-	319.42	319.42									
33	Panacea Biotech Limited		Panacea Biotech Germany		Indirectly wholly owned subsidiary	Any other transaction	Provision made on loan/advances	As approved by Audit Committee and Board	-	319.42	319.42									
34	Panacea Biotech Limited		Panacea Biotech Germany GmbH		Indirectly wholly owned subsidiary	Any other transaction	Outstanding Receivable	As approved by Audit Committee and Board	-	1.05	1.00									
35	Panacea Biotech Limited		Panacea Biotech Germany		Indirectly wholly owned subsidiary	Any other transaction	Allowance for doubtful receivable	As approved by Audit Committee and Board	-	1.05	1.00									
36	Panacea Biotech Limited		Panacea Biotech Germany		Indirectly wholly owned subsidiary	Any other transaction	Outstanding payable	As approved by Audit Committee and Board	-	20.02	18.84									
37	Panacea Biotech Pharma Ltd.		Panacea Biotech Germany		Indirectly wholly owned subsidiary of Holding Company	Any other transaction	Trade Receivable	As approved by Board	-	1.89	-									
38	Panacea Biotech Limited		Panacea Biotech Pharma Limited		Subsidiary	Interest paid		As approved by Audit Committee and Board	24.80	1.28	22.32									
39	Panacea Biotech Limited		Panacea Biotech Pharma Limited		Subsidiary	Investments		As approved by Audit Committee and Board	-	1.00	1.00									
40	Panacea Biotech Limited		Panacea Biotech Pharma Ltd.		Subsidiary	Sale of goods or services		As approved by Audit Committee and Board	0.23	-	-									



											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken										
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other Related Party Transaction	Value of the related party transaction as approved by the audit committee (Rs. in million)	Remarks on approval by audit committee	Value of transaction during the reporting period (Rs. in million)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments			Details of the loans, inter-corporate deposits, advances or investments					
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance (Rs. in million)	Closing balance (Rs. in million)	Nature of indebtedness (loan/ issuance of debt / any other etc.)	Details of other indebtedness	Cost	Tenure	Nature (loan / advance / intercorporate deposit / investment)	Interest Rate (%)	Tenure	Secured/ unsecured	Purpose for which the funds will be utilised by the ultimate recipient of funds (end-usage)
41	Panacea Biotech Limited		Panacea Biotech Pharma Ltd.		Subsidiary	Any other transaction	Rental Income		As approved by Audit Committee and Board	11.35	-	-									
42	Panacea Biotech Limited		Panacea Biotech Pharma Ltd.		Subsidiary	Purchase of goods or services			As approved by Audit Committee and Board	0.11	142.05	177.35									
43	Panacea Biotech Limited		Panacea Biotech Pharma Ltd.		Subsidiary	Purchase of fixed assets			As approved by Audit Committee and Board	0.33	-	-									
44	Panacea Biotech Limited		Panacea Biotech Pharma Ltd.		Subsidiary	Any other transaction	Reimbursement of Expenses		As approved by Audit Committee and Board	3.26	-	-									
45	Panacea Biotech Limited		Panacea Biotech Pharma Ltd.		Subsidiary	Any other transaction	Recovery of expenses		As approved by Audit Committee and Board	4.10	-	-									
46	Panacea Biotech Limited		Panacea Biotech Pharma Ltd.		Subsidiary	Loan			As approved by Audit Committee and Board	234.55	500.00	735.83									
47	Panacea Biotech Limited		PanEra Biotech Pvt. Ltd.		Associate	Any other transaction	Rental Income	0.14	As approved by Audit Committee and Board	0.08	0.34	0.42									
48	Panacea Biotech Limited		PanEra Biotech Pvt. Ltd.		Associate	Investments			As approved by Audit Committee and Board	-	4.20	4.20									
49	Panacea Biotech Limited		PanEra Biotech Pvt. Ltd.		Associate	Any other transaction	Provision for impairment of Investment		As approved by Audit Committee and Board	-	4.20	4.20									
50	Panacea Biotech Limited		PanEra Biotech Pvt. Ltd.		Associate	Advance			As approved by Audit Committee and Board	-	43.13	43.13									
51	Panacea Biotech Limited		PanEra Biotech Pvt. Ltd.		Associate	Any other transaction	Allowance for doubtful receivable		As approved by Audit Committee and Board	-	43.13	43.13									
52	Panacea Biotech Pharma Ltd.		PanEra Biotech Pvt. Ltd.		Associate of Panacea Biotech Ltd.	Interest received			As approved by Audit Committee and Board	0.11	-	0.11									
53	Panacea Biotech Pharma Ltd.		PanEra Biotech Pvt. Ltd.		Associate of Panacea Biotech Ltd.	Any other transaction	Provision made on Interest earned on loan/ advances		As approved by Audit Committee and Board	0.11	-	0.11									
54	Panacea Biotech Pharma Ltd.		PanEra Biotech Pvt. Ltd.		Associate of Panacea Biotech Ltd.	Loan			As approved by Audit Committee and Board	10.00	-	10.00					Loan	9%	3 Years	Unsecured	For meeting working capital requirements



R

											Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken									
S. No	Details of the party (listed entity /subsidiary) entering into the transaction		Details of the counterparty			Type of related party transaction	Details of other Related Party Transaction	Value of the related party transaction as approved by the audit committee (Rs. in million)	Remarks on approval by audit committee	Value of transaction during the reporting period (Rs. in million)	In case monies are due to either party as a result of the transaction		In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments				Details of the loans, inter-corporate deposits, advances or investments			
	Name	PAN	Name	PAN	Relationship of the counterparty with the listed entity or its subsidiary						Opening balance (Rs. in million)	Closing balance (Rs. in million)	Nature of indebtedness (loan/ issuance of debt / any other etc.)	Detail of other indebtedness	Cost	Tenure	Nature (loan / advance / intercorporate deposit / investment)	Interest Rate (%)	Tenure	Secured/ unsecured
55	Panacea Biotec Pharma Ltd.		PanEra Biotec Pvt. Ltd.		Associate of Panacea Biotec Ltd.	Any other transaction	Provision made on loan/advances		As approved by Audit Committee and Board	10.00	-	10.00								
56	Panacea Biotec Limited		Radhika Heights Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Rental Income		As approved by Audit Committee and Board	-	1.06	1.06								
57	Panacea Biotec Limited		Radhika Heights Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Rent & Other Expenses		As approved by Audit Committee and Board	2.59	16.38	18.97								
58	Panacea Biotec Limited		Ravinder Heights Limited		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Recovery of expenses		As approved by Audit Committee and Board	-	0.76	0.76								
59	Panacea Biotec Limited		Trinidhi Finance Pvt. Ltd.		Enterprises over which Person(s) (having control or significant influence over the Company / Key Management Personnel(s), along with their relatives) are able to exercise significant influence	Any other transaction	Trade Receivable		As approved by Audit Committee and Board	-	0.10	0.10								
Total										342	2,027.01	2,305.02								

